Gemini Therapeutics Company
Gemini Therapeutics focuses on genetically-defined dry age-related macular degeneration (AMD) and associated rare genetic diseases.
Investors Number:
3
Total Funding:
$44.5M
Investor Type:
For Profit
Technology:
Rare Genetic Disorders
Estimated Revenue:
Less than $1M
Founded Date:
2015
Employee Number:
11-50
Industry:
Gene Therapy
Headquarters:
Cambridge, Massachusetts, United States
Funding Status:
Early Stage Venture
Last Funding Type:
Series A